Mineralys Q1 net loss $31.5M; cash $338.6M; Advance-HTN topline due Q4 2024

Mineralys Therapeutics, Inc.

2024-Q1 EPS reported -$0.70

Net loss of $31.5M for Q1 2024, up from $12.6M in Q1 2023; R&D expenses $30.8M.
Cash, equivalents and investments $338.6M as of March 31, 2024; private placement net ~$116M in Q1.
Advance-HTN pivotal trial topline data expected in Q4 2024.
Launch-HTN Phase 3 trial topline data anticipated in 2H 2025.
Explore-CKD Phase 2 topline data expected Q4 2024 to Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mineralys Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $31.5 million.

Period: the quarter ended March 31, 2024
Net income: $31.5 million
Result: reported results

Exact text from the filing

Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Mineralys Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001933414-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.